Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of igd-Fc-Ig fusion protein to preparation of drug for treating rheumatoid arthritis

A igd-fc-ig, 1.igd-fc-ig technology, applied in the field of IgD-Fc-Ig fusion protein, can solve the problems of unclear functions and few studies on signaling pathways

Active Publication Date: 2018-12-11
魏伟
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the related functions of IgD / IgDR are still unclear, and there are few studies on IgD / IgDR related signaling pathways

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of igd-Fc-Ig fusion protein to preparation of drug for treating rheumatoid arthritis
  • Application of igd-Fc-Ig fusion protein to preparation of drug for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: IgD, IgD-Fc-Ig fusion protein competition binding experiment

[0023] 1.1 Experimental method

[0024] Separation of human peripheral blood CD4 by immunomagnetic beads + T cells at 2 x 10 6 The cell density per well was spread in 6-well plate, and FITC-IgD (10 μg / ml) and different concentrations of IgD-Fc-Ig fusion protein (0.03, 0.1, 0.3, 1, 3, 10, 30 μg / ml) were added respectively, 37 Incubate at ℃ for 2h. Wash twice with PBS, 300g×10min, discard the supernatant, resuspend the cells with an appropriate amount of PBS, and detect the fluorescence intensity on the machine. The binding properties of ligand IgD, IgD-Fc-Ig fusion protein and IgDR were calculated by Fluorescent Intensity (FI) values. According to the results of flow cytometry, the competition binding curve was drawn with different concentrations of IgD-Fc-Ig fusion protein as the X axis and the corresponding IgD specific binding amount as the Y axis. According to the binding curve, the IC ...

Embodiment 2

[0027] Example 2: Effects of IgD and IgD-Fc-Ig fusion protein on the proliferation and activity of peripheral blood T cells in RA patients and healthy controls

[0028] 2.1 Experimental method

[0029] 2.1.1 CCK-8 method to detect IgD and IgD-Fc-Ig on CD4 + Effects on T cell viability

[0030] Measure CD4 by CCK-8 method + T cell viability to reflect cell proliferation. CD4 after sorting + For T cells, adjust the cell concentration to 5 × 10 6 / ml, add 100 μl cell suspension culture in 96-well plate, add IgD (3 μg / ml) and IgD-Fc-Ig (1, 3, 10 μg / ml) and T cell stimulator anti-CD3 / CD28 antibody stimulation in groups, every Set up 3 replicate wells, at 37°C, 5% CO 2 Cultivate in the incubator for 24h and 48h. After terminating the culture, add 10 μl of CCK-8 to each well, and detect the A450nm value with a microplate reader 4h later.

[0031] 2.1.2 The effect of IgD and IgD-Fc-Ig on the surface activation molecules of human peripheral blood T cells detected by flow cytomet...

Embodiment 3

[0071] Example 3: The main pharmacodynamic study of IgD-Fc-Ig fusion protein on mouse collagen induced arthritis (collagen inducedarthritis, CIA)

[0072] 3.1 Experimental method

[0073] 3.1.1 Preparation of mouse collagen-induced arthritis (CIA) model

[0074] After the mice adapt to the environment (about a week), start to make models. Dissolve CCII in 0.01mol / L glacial acetic acid and grind it fully on ice to form an emulsion. After pre-cooling, it was added to the ground equal volume of collagen, and then fully ground into an emulsion, so that the final concentration of CCII and BCG was both 2 mg / ml (on ice). Inject 0.15ml of the emulsion intradermally into the base of the tail or multiple sites on the back for 21 days, prepare the same emulsion, and give a booster injection of 0.1ml to the mice again. The day of the first immunization was defined as day 0, and the overall indicators of the mice were evaluated twice a week after the booster injection.

[0075] 3.1.2 Ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an IgD-Fc-Ig fusion protein to the preparation of a drug for treating rheumatoid arthritis, wherein the IgD-Fc-Ig fusion protein has an amino acid sequence asshown in SEQ ID NO.1.

Description

technical field [0001] The present invention relates to the field of treating autoimmune diseases by using IgD-Fc-Ig fusion protein synthesized by linking human IgD-Fc segment and human IgG-Fc segment with IgD / IgDR as the target, and especially relates to IgD-Fc-Ig fusion protein Application of drugs for treating rheumatoid arthritis (RA). Background technique [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is a common, chronic autoimmune disease, its pathological features are synovial tissue inflammatory hyperplasia and progressive destruction of articular cartilage, the incidence rate of the world is about 1%, Its etiology is still not really clear. The clinical manifestations of RA are polyarthritis. In the early stage, joints such as hands, wrists, and feet are red, swollen, hot, painful, and dysfunctional. In the late stage, articular cartilage and subchondral bone destruction, joint deformity, and loss of function may occur. The prevalence of RA in my countr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K38/17A61P19/02A61P29/00
CPCA61K38/177A61K39/395A61P19/02A61P29/00A61K2300/00
Inventor 魏伟吴育晶
Owner 魏伟
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com